Arpida AG

Quick facts

Phase 3 pipeline

• Intravenous iclaprim · Infectious Disease
  Iclaprim is a dihydrofolate reductase (DHFR) inhibitor that disrupts bacterial folate metabolism, preventing DNA synthesis and bacterial growth.
• intravenous iclaprim or intravenous linezolid · Infectious disease
  Iclaprim inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit.
• Intravenous linezolid · Infectious Disease
  Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Arpida AG portfolio CI brief
• Arpida AG pipeline updates RSS